EVO Healthcare

Evotec SE

$1.55+1.97%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Germany
Market cap: 550.9M USD
Enterprise value: 756.2M USD
Full-time employees: 4,461

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.26 vs a peer median of 0.63)higher risk: bigger price swings (beta 1.26 vs peers 0.63)

Ranks #1,018 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Evotec looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to December 2025.
Evotec reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

StockQuotient Score

27/ 100

Oct 5 27 → Nov 4 27

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last year: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-10.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · EUR→USD at the current rateNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-14.8%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 months · EUR→USD convertedNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-8.3%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · EUR→USD at the current rate · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield83.0%

SEC filings (IFRS mapped) · latest balance sheet · EUR→USD at the current rateReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

39/100

Weak

3/3 inputs reported · High confidence

Since last year: No major change

Why

Weaker than most peers on:

▼ Revenue growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth1.6%

SEC filings (IFRS mapped) · 3 years to Dec 2025Reported value33% base weight · Z-score -0.50Sector median: 0.0584 · MAD: 0.0840

Revenue growth-1.1%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -0.74Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

30/100

Weak

3/3 inputs reported · High confidence

Since last year: ▲ Stronger

Operating margin rose 10.8 points to -7.1%

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-7.1%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -1.17Sector median: 0.0706 · MAD: 0.1217

Return on assets-6.0%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -1.44Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-6.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -1.13Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin14.5%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-12.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Weaker than most peers on:

▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.26

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.88Sector median: 0.6250 · MAD: 0.3380

Current ratio2.07×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -0.37Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.34×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -0.58Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Evotec

Is Evotec getting weaker?: Its latest SEC filing (Apr 8, 2026) got stronger: operating margin rose 10.8 points to -7.1%. Its overall score is unchanged at 27/100 since Oct 28, 2026.
How is Evotec valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -10.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -10.6% vs peers 1.5% (weaker than 100% of peers).
Is Evotec growing?: More slowly than most of its peers. Growth scores 39/100 against 1,393 healthcare peers. Revenue growth -1.1% vs a peer median of 6.1% (weaker than 72% of peers).Revenue growth -1.1% vs peers 6.1% (weaker than 72% of peers).
How profitable is Evotec?: Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Operating margin -7.1% vs a peer median of 7.1% (weaker than 73% of peers).Operating margin -7.1% vs peers 7.1% (weaker than 73% of peers).
How risky is Evotec?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.26 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.26 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Dec 31, 2025 · filed Apr 8, 2026 · compared with the year ended Dec 31, 2024

Got stronger

Operating margin rose 10.8 points to -7.1%

	Previous year	Latest year	Change
Revenue (12 months)	797.0M EUR	788.4M EUR	−1.1%
Net income (12 months)	−196.1M EUR	−103.5M EUR	−47.2%
Operating margin	-17.9%	-7.1%	+10.8 pts
Free cash flow (12 months)	−99.2M EUR	−81.7M EUR	−17.7%
Debt	287.6M EUR	276.4M EUR	−3.9%
Cash	306.4M EUR	418.5M EUR	+36.6%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year · amounts in EUR, as reported

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	24.5%	23.2%	22.4%	14.4%	14.5%	▲ 0.1 pts
Operating margin	6.6%	2.8%	-6.1%	-17.9%	-7.1%	▲ 11 pts
Net margin	34.9%	-23.4%	-10.7%	-24.6%	-13.1%	▲ 11 pts
Return on assets (ROA)	9.6%	-7.8%	-3.7%	-10.3%	-6.0%	▲ 4.2 pts
Return on equity (ROE)	15.6%	-14.8%	-7.5%	-20.6%	-12.7%	▲ 7.9 pts
Free cash flow margin	1.2%	3.3%	-22.6%	-12.5%	-10.4%	▲ 2.1 pts
Current ratio	3.39×	3.18×	1.94×	1.98×	2.07×	▲ 4.7%
Quick ratio	3.31×	3.09×	1.88×	1.89×	1.99×	▲ 5.5%
Debt to equity	0.26×	0.28×	0.39×	0.30×	0.34×	▲ 13%
Interest coverage	4.43×	1.59×	—	—	—	—

EVO price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.26 vs a peer median of 0.63)higher risk: bigger price swings (beta 1.26 vs peers 0.63)

Ranks #1,018 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Evotec looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to December 2025.

Evotec reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Questions investors ask about Evotec

Is Evotec getting weaker?

Its latest SEC filing (Apr 8, 2026) got stronger: operating margin rose 10.8 points to -7.1%. Its overall score is unchanged at 27/100 since Oct 28, 2026.

How is Evotec valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -10.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -10.6% vs peers 1.5% (weaker than 100% of peers).

Is Evotec growing?

More slowly than most of its peers. Growth scores 39/100 against 1,393 healthcare peers. Revenue growth -1.1% vs a peer median of 6.1% (weaker than 72% of peers).Revenue growth -1.1% vs peers 6.1% (weaker than 72% of peers).

How profitable is Evotec?

Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Operating margin -7.1% vs a peer median of 7.1% (weaker than 73% of peers).Operating margin -7.1% vs peers 7.1% (weaker than 73% of peers).

How risky is Evotec?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.26 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.26 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Revenue (12 months)

797.0M EUR

788.4M EUR

−1.1%

Net income (12 months)

−196.1M EUR

−103.5M EUR

−47.2%

Operating margin

-17.9%

-7.1%

+10.8 pts

Free cash flow (12 months)

−99.2M EUR

−81.7M EUR

−17.7%

Debt

287.6M EUR

276.4M EUR

−3.9%

Cash

306.4M EUR

418.5M EUR

+36.6%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

24.5%

23.2%

22.4%

14.4%

14.5%

▲ 0.1 pts

Operating margin

6.6%

2.8%

-6.1%

-17.9%

-7.1%

▲ 11 pts

Net margin

34.9%

-23.4%

-10.7%

-24.6%

-13.1%

▲ 11 pts

Return on assets (ROA)

9.6%

-7.8%

-3.7%

-10.3%

-6.0%

▲ 4.2 pts

Return on equity (ROE)

15.6%

-14.8%

-7.5%

-20.6%

-12.7%

▲ 7.9 pts

Free cash flow margin

1.2%

3.3%

-22.6%

-12.5%

-10.4%

▲ 2.1 pts

Current ratio

3.39×

3.18×

1.94×

1.98×

2.07×

▲ 4.7%

Quick ratio

3.31×

3.09×

1.88×

1.89×

1.99×

▲ 5.5%

Debt to equity

0.26×

0.28×

0.39×

0.30×

0.34×

▲ 13%

Interest coverage

4.43×

1.59×

—